BAVA Bavarian Nordic A/S

New Incentive Programs Established for Members of Executive and Other Management in Bavarian Nordic

New Incentive Programs Established for Members of Executive and Other Management in Bavarian Nordic

 

COPENHAGEN, Denmark, April 1, 2022 – In accordance with the Company’s remuneration policy, the Board of Directors of Bavarian Nordic A/S has today decided to establish new incentive programs for members of the executive and other management in the Company, including Russell Thirsk, newly appointed Executive Vice President and Chief Operating Officer.

Under the program, a total of 6,669 restricted stock units are awarded to Russell Thirsk, including matching shares which will be granted upon expiry of a 3-year period after the award date at a ratio of 1:2, i.e., one matching share will be granted for each two restricted stock units. The acquisition of restricted stock units is conditional upon the recipient not having passed away prior to the expiry of the program on April 1, 2025. The grant of matching shares is further conditioned by the recipient still being employed at expiry of the program. The value of one restricted stock unit is DKK 110.21, based on an average of the closing price of the Company's shares over a period of 15 trading days prior to today and when adjusting for matching shares.

Furthermore, in accordance with the shareholder authorization for the Board of Directors adopted as Article 5b of the Articles of Association, a new warrant program is established. A total of 81,872 warrants are granted to Russell Thirsk and other management in the Company, which entitle the warrant holders to subscribe for up to 81,872 shares in total with a nominal value of DKK 10 each at an exercise price of DKK 190.11 per share. The warrants may be exercised wholly or partly during eight fixed subscription periods, starting after the announcement of the Company’s interim results for the first half 2025. The value of each warrant equals DKK 46.55 and is calculated on the Black-Scholes model with a risk-free interest rate of 0.39 per cent and on the historical volatility of the shares. The calculation is based on a share price of DKK 171.35.

As a consequence of the aforementioned grants of restricted stock units and warrants to Executive Vice President and Chief Operating Officer, Russell Thirsk, the following transactions of the Company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such are hereby reported in accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523.

1.Details of the person discharging managerial responsibilities/person closely associated  
a)NameRussell Thirsk
2.Reason for the notification
a)Position/status



 
Executive Vice President and Chief Operating Officer of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument





Identification code
Restricted Stock Units





DK0015998017
b)Nature of the transactionGrant
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 110.21     6,669
d)Aggregated information
  • Aggregated volume
  • Price
 



6,669

DKK 735,000.00
e)Date of the transaction2022-04-01
f)Place of the transactionOutside a trading venue

 

1.Details of the person discharging managerial responsibilities/person closely associated  
a)NameRussell Thirsk
2.Reason for the notification
a)Position/status



 
Executive Vice President and Chief Operating Officer of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument





Identification code
Warrants





DK0015998017
b)Nature of the transactionGrant
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 0.00         63,157
d)Aggregated information
  • Aggregated volume
  • Price
 



63,157

DKK 0.00
e)Date of the transaction2022-04-01
f)Place of the transactionOutside a trading venue

About Bavarian Nordic

Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacturing and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Government of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. The vaccine is approved as a smallpox vaccine in Europe and Canada. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, which is licensed to the Janssen Pharmaceutical Companies of Johnson & Johnson. We are also committed to the development of a next generation COVID-19 vaccine. For more information visit .

Contacts

Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel:

US: Graham Morrell, Paddock Circle Advisors, , Tel:

Company Announcement no. 09 / 2022

Attachment



EN
01/04/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bavarian Nordic A/S

 PRESS RELEASE

Paul Chaplin fratræder som administrerende direktør i Bavarian Nordic

Paul Chaplin fratræder som administrerende direktør i Bavarian Nordic KØBENHAVN, Danmark, 2. marts 2026 – Bavarian Nordic A/S (OMX: BAVA) offentliggjorde i dag, at bestyrelsen har indgået en aftale med administrerende direktør, Paul Chaplin, som ønsker at træde tilbage af personlige årsager. Paul Chaplin vil fortsætte i sin rolle indtil udgangen af 2026 eller indtil en efterfølger er identificeret. Bestyrelsen har igangsat processen med at identificere en ny administrerende direktør. Paul Chaplin har været hos Bavarian Nordic siden 1999 og blev udnævnt til administrerende direktør i 2014....

 PRESS RELEASE

Paul Chaplin Steps Down as CEO of Bavarian Nordic

Paul Chaplin Steps Down as CEO of Bavarian Nordic COPENHAGEN, Denmark, March 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today, that the Board of Directors has entered into an agreement with CEO, Paul Chaplin, who wishes to step down for personal reasons. Paul Chaplin will continue in his role for the remainder of 2026, or until a successor has been identified. The Board of Directors has initiated the process to identify a new CEO. Paul Chaplin has been with Bavarian Nordic since 1999 and was appointed CEO in 2014. He has led the development of the Company’s smallpox and mpox vacci...

 PRESS RELEASE

Bavarian Nordic offentliggør foreløbige resultater for 2025 og forvent...

Bavarian Nordic offentliggør foreløbige resultater for 2025 og forventninger til 2026 Resultatet overgår de seneste forventninger til 2025 efter en stærk udvikling i begge kommercielle forretningsben, Travel Health og Public Preparedness.Forventningerne til 2026 afspejler en fortsat vækst i Travel Health (10% fra egne produkter, 14% i konstant valuta) og et normaliseret år inden for Public Preparedness, begge områder i overensstemmelse med selskabets offentliggjorte vækstambitioner på mellemlang sigt. KØBENHAVN, Danmark, 12. februar 2026 – Bavarian Nordic A/S (OMX: BAVA) offentliggjorde i ...

 PRESS RELEASE

Bavarian Nordic Reports Preliminary 2025 Financial Results and Provide...

Bavarian Nordic Reports Preliminary 2025 Financial Results and Provides Guidance for 2026 Exceeding latest 2025 guidance following a strong performance from both commercial arms of the business in Travel Health and Public Preparedness.2026 guidance reflects continued growth in Travel Health (10% from own products, 14% at constant exchange rates) and a normalized year in Public Preparedness, both in line with the communicated mid-term growth ambitions. COPENHAGEN, Denmark, February 12, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced preliminary, unaudited financial results for 2025 a...

 PRESS RELEASE

Bavarian Nordic – afslutning af aktietilbagekøbsprogram

Bavarian Nordic – afslutning af aktietilbagekøbsprogram KØBENHAVN, Danmark, 9. februar 2026 – Bavarian Nordic A/S (OMX: BAVA) meddeler, at aktietilbagekøbsprogrammet, der blev offentliggjort og iværksat den 7. januar 2026, nu er afsluttet, da aktier til en samlet værdi af ca. DKK 150 mio. er tilbagekøbt som planlagt. Dette udgjorde den første del af et samlet planlagt aktietilbagekøb på op til DKK 500 mio. i løbet af 2026. Bavarian Nordic vil beholde de tilbagekøbte aktier som egne aktier med det formål at tilpasse kapitalstrukturen. Programmet blev gennemført i overensstemmelse med bestem...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch